(S)-1-BOC-4-OXOPIPERIDINE-2-CARBOXYLIC ACID, 97.0%, 250mg

3,4,5,6-Tetrachloropicolinonitrile, 95.0%, 250mg

3-Bromo-2,5-dimethylpyridine, 95.0%, 250mg

Methyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate, 95.0%, 1g

Diethylene Glycol (DEG), 99.0%, 500g

TERT-BUTYL (3R)-3-[[(BENZYLOXY)CARBONYL]AMINO]PIPERIDINE-1-CARBOXYLATE, 97%, 10g

1-(3-BROMOPHENYL)CYCLOBUTANECARBONITRILE, 95.0%, 250mg

Fmoc-(R)-3-amino-3-(3-trifluoromethylphenyl)-propionic acid, 97%, 10g

(Z)-Ethyl 2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetate, 97%, 10g

Plan PLPH 10x/0.25 phase contrast objective

2-Mesityl-2,5,6,7-tetrahydropyrrolo[2,1-c][1,2,4]triazol-4-ium chloride, 95%, 100mg

(3-Bromo-2-fluoro-4-methoxyphenyl)methanol, 98%, 10g

Methyl 5-(aminomethyl)-2-furoate, 95+%, 250mg